Methods and results
Introduction
We developed the technique of continuous subcutaneous insulin infusion'-6 as a means of achieving near-normoglycaemia in insulin-dependent diabetics for periods long enough to test the hypothesis that strict metabolic control may slow, prevent, or reverse the progress of diabetic microvascular disease.
Other workers recently confirmed the inpatient and outpatient efficacy of the system in small groups of diabetics.7
A randomised, controlled, prospective trial of the effect of diabetic control on complications requires a large number of patients studied for prolonged periods, perhaps many years. It is therefore important to establish the tolerance to outpatient treatment with continuous subcutaneous insulin infusion in patients with a wide range of occupations, life styles, intelligence, and clinical features of diabetes. Their response to the "firstgeneration" insulin infusion pumps may also provide valuable guidance on future technological developments and indicate the constraints of long-term trials.
We therefore report the responses elicited by a questionnaire sent to diabetics treated at home by continuous subcutaneous infusion for three weeks or more. Unit The figure shows the questionnaire, which was sent to the first 15 insulin-dependent diabetics who had been treated as outpatients with continuous subcutaneous insulin infusion for three weeks or more. Table I shows the clinical features and occupations of the patients. One patient did not return the questionnaire.
The questionnaire. Tables II and III show the responses of the patients to questions 4, 5, 6, and 8 on the questionnaire. In reply to the question "Did you feel that you understood the pump ?" (question 7) all patients answered yes. building work) obviously presented more difficulties, more because of the bulk of the system than because of exerciseinduced hypoglycaemia. Such hypoglycaemia, in fact, is rarely noted during continuous subcutaneous insulin infusion and seems to be much less common than during conventional treatment by insulin injection.6 12 It was encouraging that almost all of the patients thought that diabetic control was better during treatment by continuous subcutaneous infusion than injections, and several felt better in themselves while receiving the infusion. The increased flexibility of diet and insulin regimens was often commented onthat is, the facility to delay or even omit meals altogether on occasions, to alter the basal insulin infusion rate independently of the timing and size of the prandial insulin boost, and to vary the boost with the expected size of the meal.
Physical reactions to the infusion system centred mostly on the size of the pump (the Mill Hill infuser measures 7 x 14 5 x 2-3 cm). Several patients found it uncomfortable at night and awkward to secure to the body, particularly in a harness. Women remarked on the restrictions and alterations sometimes necessary with fashionable clothing. One patient was conscious of the noise of the pump motor, although generally we find that this quickly becomes unnoticed by the wearer. 2 All patients considered that they understood the principle and the operation of the pump system, indicating that the present controls are adequately simple.
Psychological reactions were notable. Many patients remarked that the treatment made them more aware of being a diabetic, which they usually regarded unfavourably. Partly this was because others noticed the device, were curious about it, and might embarrass the patients. The increased attention to and supervision of these diabetics probably also highlighted their condition.
Reliance on a mechanical device for life-supporting drug delivery might be expected to produce considerable unease. Some patients were thought of by others, or even themselves, as "robots," at least at first, but it is surprising that the patients did not express more anxiety about system failure. None asked for audible warnings of possible events such as battery discharge or other pump malfunction, although several new pump designs will incorporate these features.
Sexual relations and sporting activities might be restricted when the pump is being worn, and it is obviously important that full discussion with the patient and patient's spouse or partner takes place before treatment begins. After deliberate removal of the infusion pump blood glucose concentrations remain stable for about one hour before beginning to rise. 13 Patients should be advised that disconnecting the system for bathing, sexual intercourse, etc, is perfectly safe for this period.
Despite the above strictures nine patients indicated that they would undertake continuous subcutaneous infusion for one year and a further two that they would do so if the infuser were smaller. Almost all the patients agreed that the infuser should be smaller, emphasising that future work should be directed towards miniaturising the infuser. In our laboratory we have developed a prototype pump about one-third the size and weight of the Mill Hill infuser, and other small secondgeneration devices are currently undergoing clinical trials elsewhere. Other suggestions for future development such as separate and easily variable day-time and night-time basal infusion rates have been incorporated in new prototype pumps. These new pumps should greatly improve the long-term acceptability of continuous subcutaneous infusion. Though this questionnaire was sent to only the first 15 patients who received prolonged outpatient treatment with this method, we are continuing to elicit patient responses as pump technology and infusion techniques improve. The purpose of the present study was to test for associations between pernicious anaemia and HLA-DR antigens and to determine what bearing these might have on the pathogenesis of pernicious anaemia and its relation to autoimmune endocrine disease.
Patients and methods
We studied 66 unrelated Caucasians with pernicious anaemia who attended this hospital for treatment or review during 1979-80. They comprised 25 men and 41 women aged 20 to 94 years (mean age 66 5 years) who satisfied the standard diagnostic criteria for Addisonian pernicious anaemia.2 All had impaired vitamin B,2 absorption, shown by a Schilling test result of 0-50,' . Serum antibodies to human parietal cells were present in 60 patients and to intrinsic factor in 31.
Of the 66 patients, 48 (17 men and 31 women) were clinically free of endocrine disease ("non-endocrine" subgroup), while 18 (eight men and 10 women) had known endocrine disease ("endocrine" subgroup). Three of these patients (including one diabetic) had thyrotoxicosis due to Graves's disease, five had primary myxoedema, one (a diabetic) had idiopathic Addison's disease of the adrenals, one had myasthenia gravis, and 10 had diabetes mellitus (seven were dependent on insulin). 
